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Abstract 
Background: Controlled human malaria infection (CHMI) has become well-established in the evaluation of drugs 
and vaccines. Anti-malarial treatment is usually initiated when thick blood smears are positive by microscopy. This 
study explores the effects of using the more sensitive qPCR as the primary diagnostic test.
Methods: 1691 diagnostic blood samples were analysed by microscopy and qPCR from 115 volunteers (55 malaria 
naïve and 60 having received chemoprophylaxis and sporozoite immunization) who were challenged by five mosqui-
toes infected with Plasmodium falciparum sporozoites of the NF54 strain.
Results: Retrospective analysis of different qPCR criteria for diagnosis and treatment, showed that once daily qPCR 
(threshold 100 parasites/ml) had 99 % sensitivity and 100 % specificity, and shortened the median prepatent period 
from 10.5 to 7.0 days after CHMI when compared to twice daily measurement of thick blood smears (threshold 4000 
parasites/ml). This is expected to result in a 78 % decrease of adverse events before initiation of treatment in future 
studies. Trial outcome related to infection and protective efficacy remained unchanged.
Conclusion: The use of qPCR as the primary diagnostic test in CHMI decreases symptoms as well as parasitaemia 
while obviating the need for twice daily follow-up. The implementation improves safety while reducing the clinical 
burden and costs without compromising the evaluation of protective efficacy.
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Background
Controlled human malaria infection (CHMI) has proven 
to be a valuable tool to evaluate the efficacy of drugs and 
vaccines and to study the pathogenesis of clinical malaria. 
These challenge trials have become highly standardized 
[1] and are considered a critical step in the clinical devel-
opment of pre-erythrocytic malaria vaccines [2].
Traditionally, volunteers are followed after CHMI by 
once to three times daily thick blood smears, and anti-
malarial treatment is initiated immediately once two or 
more parasites are detected by microscopy. In 2004, a 
standardized protocol for CHMI thick blood smears 
was introduced using a threshold of 4000 parasites/ml to 
improve the comparability of study outcomes between 
centres [3]. Volunteers generally develop submicroscopic 
parasitaemia for several days before they become thick 
smear positive. The more sensitive quantitative PCR 
(qPCR) with a detection limit of 20 parasites/ml was 
introduced for retrospective analysis feeding a statistical 
model for more detailed estimation of important parasite 
parameters including liver load and asexual parasite mat-
uration and multiplication rates [4, 5].
Over the past decade, CHMIs have been performed 
in over 300 healthy volunteers at Radboud university 
medical center (Radboudumc), the ‘Harbour Hospital’ 
in Rotterdam or the Leiden University Medical Centre 
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(LUMC). Despite an acceptable safety profile, CHMIs 
inevitably cause mild to moderate malaria symptoms 
such as headache, myalgia and malaise in almost all vol-
unteers, and severe (grade 3) symptoms in about half of 
volunteers [3, 6]. Moreover, there have been three serious 
adverse cardiac events shortly after treatment for parasi-
taemia that have remained incompletely understood [7, 
8]. As clinical malaria symptoms are only associated with 
asexual blood stages, a shorter duration of parasitaemia 
may reduce the number and severity of adverse events, 
thereby further minimizing risks and volunteer burden. 
In addition, treating volunteers before (severe) symptoms 
occur, would simplify the conduct and follow-up, thereby 
lowering costs.
In this retrospective study, different thresholds for 
qPCR diagnostics were analyzed in relation to prepatent 
period and occurrence of adverse events as well as effects 
on assessment of protective efficacy.
Methods
Study volunteers
Retrospective qPCR data that had previously been gen-
erated were collected from nine CHMI trials performed 
at the Radboud university medical center (Radboudumc), 
the ‘Harbour Hospital’ in Rotterdam or the Leiden Uni-
versity Medical Centre (LUMC) between 2007 and 2012 
[9–15], Table 1.
All study subjects were healthy female and male vol-
unteers between the age of 18 and 35  years exposed 
to bites of five Plasmodium falciparum NF54 strain 
infected Anopheles stephensi mosquitoes. Prior to chal-
lenge infection, 55 volunteers were malaria naïve and 60 
had received chemoprophylaxis and sporozoite (CPS) 
immunization. CPS-immunization was administered via 
infected mosquito bites at different dosages under chlo-
roquine or mefloquine prophylaxis, as described previ-
ously [10–14].
Prior to inclusion, study volunteers were medically 
screened as described previously [13] and provided writ-
ten informed consent. All clinical trials were approved 
by the Radboudumc Committee on Research Involv-
ing Human Subjects (CMO) or the Central Committee 
on Research Involving Human Subjects (CCMO) of the 
Netherlands.
Parasitological data
Treatment was initiated after CHMI when a thick blood 
smear was found positive for parasites. Thick smears 
were made twice or three times daily and read accord-
ing to a standard protocol [11]. In short, a slide was 
considered positive if after reading the number of fields 
equivalent to 0.5 μL of blood at least two parasites were 
seen (a threshold of four parasites per µL), and positiv-
ity was confirmed by a second independent reader. qPCR 
Table 1 Summary of data included in the analysis
Data was included from all malaria naïve or CPS-immunized volunteers undergoing challenge infection with bites from five mosquitoes infected NF54 since 2007
a Only volunteers with patent parasitemia included. In all studies pre-patent period is defined as time to positive thick blood smear
b Volunteers received three immunization with a candidate malaria vaccine but were unprotected from challenge infection
c Rechallenge of CPS-immunized volunteers from Study 1, 2.5 years after immunization and malaria naive controls
Year Number of  
volunteers
CPS-immunization Patent  
parasitemia
Pre-patent perioda References
Median Range
Study 1 2007 10 3 × 12–15 mosquitoes 0/10 – – Roestenberg et al. [13]
5 – 5/5 9 7–10.5
Study 2b 2007 18 – 18/18 10.5 9–12.5
Study 3 2009 6 3 × 12–15 mosquitoesc 2/6 16.8 15–18.6 Roestenberg et al. [14]
4 – 4/4 8.5 7.5–10.5
Study 4 2010 5 – 4/5 10.6 10.6–11 Teirlinck et al. [15]
Study 5 2011 5 3 × 15 mosquitoes 1/5 12 – Bijker et al. [12]
9 3 × 10 mosquitoes 1/9 12 –
10 3 × 5 mosquitoes 5/10 11 9–15
5 – 5/5 9.5 9–13.5
Study 6 2011 5 3 × 15 mosquitoes 0/5 – – Bijker et al. [10]
5 – 5/5 12.5 9.5–12.5
Study 7 2012 15 3 × 8 mosquitoes 5/15 12 11–14 Bijker et al. [11]
4 – 4/4 8.5 7–12
Study 8 2012 5 – 5/5 10.5 9–10.5
Study 9 2012 5 – 5/5 12 10.5–16 Bastiaens et al. [9]
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assessment was performed according to previously pub-
lished protocols [16]. qPCR was performed retrospec-
tively from samples taken twice per day from day 5 until 
day 15 after challenge and once per day from day 16 until 
day 21.
Recording of adverse events
Subjects were asked to keep a diary recording symptoms 
while followed up for adverse events (AEs) on an out-
patient basis once or twice daily starting on day 5 after 
challenge infection until day 21. Adverse events were 
collected until end of study visits either on day 28 or day 
35 after challenge, depending on the study. An adverse 
event was defined as any undesirable symptom occurring 
after challenge infection. AEs were defined as grade 1, 
no interference with daily activity; grade 2, some inter-
ference with daily activity; or grade 3, requiring bed rest. 
The following symptoms were solicited: fever, headache, 
malaise, fatigue, myalgia, arthalgia, nausea, vomiting, 
chills, diarrhoea and abdominal pain.
Statistical analysis
Depending on the study, qPCR data was analysed using 
Microsoft Excel (version 2007) for Windows or using 
a specialized electronic Case Report Form program 
(Hermsen Computer Services) created for Radboudumc 
CHMI trials. Data was combined using Microsoft Excel 
2007 for Windows and statistical analysis was performed 
using IBM SPSS Statistics 22 for Windows.
Results
Fifty-five malaria naïve volunteers in nine trials received 
a challenge infection with bites from five NF54 infected 
mosquitoes. Geometric mean parasitaemia curves gener-
ated from retrospective qPCR data were similar between 
trials, Fig.  1a. These volunteers received anti-malarial 
treatment at positive thick blood smear at a median of 
10.5  days post-challenge (range 7.0–16.0). Based on the 
retrospective qPCR data, initiating treatment based on 
qPCR can gradually decrease the duration of parasitae-
mia, depending on the treatment threshold and blood 
sampling frequency used, Fig.  1b. When two consecu-
tive positive qPCR measurements above 500 parasites/
ml are used as a criterion to initiate treatment, volunteers 
are treated at a median of 9 days post CHMI. When only 
a single positive qPCR is required to initiate treatment, 
the mean day of treatment decreases further. Using the 
threshold of 100 parasites/ml blood, the median duration 
of parasitaemia would decrease by 3.5 days.
All solicited adverse events that were possibly, probably 
or definitively related to the CHMI occurring between 
day 5 post-infection and the end of the study were col-
lected. Fifty-five percent of all adverse events and 39 % of 
severe adverse events occurred prior to the initiation of 
anti-malarial treatment (Fig. 1c). Importantly, only 22 % 
of the total adverse events and 13  % of grade 3 adverse 
events before treatment occurred before parasitaemia 
reached 100 parasites/ml (Fig. 1d).
Once daily blood sampling for qPCR (threshold of 100 
parasites/ml), instead of twice daily sampling, did not 
influence the median treatment day, Fig. 1b. Five volun-
teers (9  %) would have been treated 24  h earlier when 
sampling for qPCR twice daily. However, the mean num-
ber of adverse events before treatment increased only 
minimally when once daily sampling was used, Fig. 1d.
CPS immunization induces dose-dependent protection 
against CHMI [12]. Partial protection was determined 
by time to parasitaemia and mean parasite density of 
the first wave, as estimation of the liver parasite load [4]. 
Since both parameters depend on the method of parasite 
detection and treatment threshold used, it was retrospec-
tively assessed whether the proportion of volunteers with 
partial protection changed with qPCR sampling once 
daily and initiation of treatment based on a single qPCR 
above 100 parasites/ml. Table  2 shows that differences 
in pre-patent period and mean parasitaemia of the first 
wave for ten partially protected volunteers and controls 
[11, 12] gave similar outcomes when using microscopy or 
qPCR.
A tentative diagnostic replacement of microscopy by 
qPCR requires a reliable test outcome. A total of 778 ret-
rospective qPCR tests have been performed in 35 fully 
protected volunteers without a single qPCR above 100 
parasites/ml. In the same studies, performed between 
2010 and 2012, 107 qPCR standard curves were gener-
ated using serial dilutions of blood samples with known 
parasite densities, diluted from isolated ring stages whose 
concentration had been determined by microscopy. At 
densities of 20, 50 and 100 parasites/ml, the parasitaemia 
in these samples was correctly quantified (less than 5 % 
deviation between duplo samples) in 63 % (57/107), 87 % 
(93/107) and 96 % (103/107) of the samples, respectively. 
With recent introduction of a new standardized reagents 
mix for the DNA extraction in 2014 (MagNA Pure LC 
Total Nucleic Acid Isolation Kit, Roche Diagnostics), 81 
of 82 standard curve samples with 100 parasites/ml and 
79 of 82 samples with 50 parasites/ml were correctly 
measured. The combined data indicate that qPCR with 
threshold of 100 parasites/ml can be reliably used for 
diagnosis in the CHMI model, with a sensitivity of 99 % 
and a specificity of 100 %.
Discussion
This retrospective qPCR analysis shows that the duration 
of blood stage parasitaemia in CHMI volunteers can be 
shortened by 3.5 days compared to thick blood smear if 
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a treatment threshold of 100 parasites/ml is used. This 
threshold has a sensitivity of 99  % and a specificity of 
100 %.
Shortening the duration of parasitaemia in volun-
teers after CHMI has several potential advantages. Most 
importantly, an increase in safety as malaria symptoms 
are related to the height and duration of parasitaemia, 
and the potential to greatly decrease the burden for vol-
unteers. Over half the adverse events after CHMI occur 
prior to thick smear positivity. This analysis shows that 
anti-malarial treatment of volunteers when parasitae-
mia reaches 100 parasites/ml will lead to a 78  % reduc-
tion in the number of adverse events occurring before 
treatment. Presumably, treatment of volunteers at lower 
parasitaemia will also lead to a decrease in adverse events 
occurring after treatment.
If prospective qPCR diagnostics are introduced with a 
low threshold (100 parasites/ml), once daily blood sam-
pling will suffice without the need for a second sample 
within 24  h, as there appears to be only a slight effect 
on the duration of parasitaemia and/or the number of 
adverse events. Five volunteers (9  %) would have been 
treated 24 h earlier when sampling for qPCR twice daily. 
Notwithstanding, we still favour once daily sampling con-
sidering the great burden of twice-daily blood sampling 
and the absence of a significant increase in the number 
of AEs at that very low parasitaemia. Shortening the 
duration of parasitaemia and decreasing the frequency 
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Fig. 1 Parasitaemia at different thresholds of qPCR and association with adverse events. a Mean parasitaemia by qPCR from a total of 55 malaria 
naïve volunteers undergoing CHMI by five NF54 infected mosquito bites in nine trials. b Day of positive thick smear or positive qPCR at differ-
ent parasite density thresholds as starting day of curative treatment. Box-and-whisker plots show the median, first and third quartiles and 5–95th 
percentiles. Numbers above the x-axis are median treatment days. c The mean number of adverse events per volunteer occurring prior to and after 
treatment. Gray total adverse events, Black grade 3. d The mean number of adverse events per volunteer occurring prior to thick smear positivity 
compared to different parasite thresholds for initiation of treatment. Percentages above the bars show the percentage of total AEs that occur rela-
tive to thick smear. Black grade 3, dark gray grade 2, light gray grade 1
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of blood sampling will significantly reduce the follow-up 
of CHMI volunteers. Given the intensive visit schedule 
for volunteers, requiring multiple personnel and safety 
laboratory evaluations, the reduced follow-up period will 
substantially simplify the conduct of these trials, which 
will also lower CHMI costs.
However, these benefits should not compromise the 
scientific value of the trial. This study shows that using 
these diagnostic criteria will not impede the ability to dis-
criminate the delay in parasitaemia and/or reduction in 
mean first wave parasitaemia as proxy for parasite liver 
stage development that occurs when a vaccine provides 
partial pre-erythrocytic protection. Therefore, using once 
daily qPCR with 100 parasites/ml threshold will likely 
provide a similar primary outcome of protective vac-
cine efficacy in prospective studies. However, the stand-
ard deviations of both mean time to parasitaemia and 
mean first wave parasitaemia in the vaccination groups 
increased in this analysis. Consequently, when a rela-
tively smaller difference is anticipated between vaccinees 
and controls, use of these qPCR criteria may require an 
increase in sample size to obtain sufficient statistical 
power.
Evaluation of qPCR data from 35 CPS-immunized 
and protected volunteers shows that since the intro-
duction of the current qPCR method at Radboudumc, 
LUMC and the Harbour Hospital in 2010, no immu-
nized and fully protected volunteers developed a positive 
qPCR after challenge above 100 parasites/ml. Using this 
qPCR method, parasites can be detected at a threshold 
of 50 parasites/ml with about 96 % sensitivity and at 100 
parasites/ml with 99  % sensitivity. Therefore, the test 
clearly has sufficient accuracy for diagnostic purposes at 
these centres. A possible hazard of using a single posi-
tive qPCR as a criterion to initiate treatment is the risk 
of false-positives by cross-contamination or accidental 
sample switching, especially since treatment will now 
often be initiated in the absence of clinical symptoms. To 
minimize this risk, it is important to set up quality con-
trol steps not only within the qPCR test but in the con-
duct and logistics of the qPCR as well. Prior to a CHMI 
study, qPCR standards are generated and validated, and 
the same standard is used throughout an entire study. 
In order to ensure comparability of CHMI data between 
centres it will be a logical next step to standardize the 
PCR assay, or make commercially available P. falciparum 
qPCR standards.
Andrews et  al. [17] first demonstrated the increased 
sensitivity of qPCR compared to thick smear, and recog-
nized that qPCR could be used to initiate earlier treat-
ment, at a threshold of 1000 parasites/ml [17]. However, 
recent advances in qPCR methodology, such as the use 
of an automated system for extraction, has improved 
sensitivity at low parasite densities. The current analysis 
shows that this has made it possible to lower the treat-
ment threshold much further. Likewise, other CHMI 
study centres have also repeatedly shown that qPCR 
first becomes positive 2–4 days before thick blood smear 
when both are determined [18–21]. Similarly, stud-
ies assessing blood stage drugs or vaccines have already 
begun to use qPCR as a primary outcome, and have 
confirmed its sensitivity and specificity [22]. In 2014 
Kamau et  al. analysed parasitological data from 16 sub-
jects undergoing CHMI in two trials. They also showed 
that qPCR is positive 2–7  days before thick smear [23]. 
Based on their analysis, the authors recommend treat-
ment after CHMI after two (not necessarily consecutive) 
positive qPCRs of which one is above 2000 parasites/
ml. This threshold was chosen to assess parasite multi-
plication rates requiring at least two replication cycles. 
Table 2 Partial protection after CPS immunization as detected by thick smear or retrospective qPCR
Differences between mean pre-patent periods were determined by Mann–Whitney U test in ten partially protected and nine control volunteers after CPS 
immunization [11, 12]. Parasitaemia of the first parasite wave was estimated by determining the geometric mean parasitaemia from 6.5 to 8.0 days after challenge. 
Differences in the mean parasitaemia of the first peak was determined by an independent samples t test
a Threshold of 4000 parasites/ml and twice daily blood sampling
b Only volunteers with patent parasitemia included in the analyis
c Threshold of 100 parasites/ml and once daily blood sampling
Number Pre-patent period (days) Parasitemia 1st peak (log)
Mean SD P value Mean SD P value
Positive thick smeara
 CPS-immunized (partially protected)b 10 12.2 1.85 0.006 1.00 0.56 0.02
 Controls (unprotected) 9 9.7 2.05 2.07 1.07
Positive qPCRc
 CPS-immunized (partially protected)b 10 9.6 2.06 0.035 1.10 0.67 0.04
 Controls (unprotected) 9 7.9 1.83 1.99 1.06
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For evaluation of pre-erythrocytic vaccines, however, 
a treatment threshold of 100 parasites/ml will be suffi-
ciently adequate. This analysis shows that different qPCR 
thresholds can be chosen to assess the duration of para-
sitaemia. For example, using two consecutive positive 
qPCRs above 500 parasites/ml as a threshold, prolongs 
the median pre-patent period to 9 days. Different qPCR 
treatment thresholds will therefore lead to different dura-
tions of parasitaemia. In this way, CHMI can be made a 
fit-for-purpose model matching the diagnostic qPCR 
protocol with the considered primary endpoints.
Although retrospective analyses should be interpreted 
prudently in general, the predictive value of this study 
can likely be met with confidence since retrospective 
qPCR data have been remarkably consistent over time 
between CHMI trials, and CHMI centres [3]. Therefore, 
PCR may be preferred for diagnosis and treatment when 
evaluating the protective efficacy of pre-erythrocytic vac-
cines [19].
Conclusions
After CHMI, qPCR becomes positive on average 
3.5  days before thick blood smear. This analysis shows 
that depending on the threshold used, treatment based 
on qPCR diagnostics can greatly reduce the pre-patent 
period and the number of AEs occurring before treat-
ment. Furthermore, these data demonstrate for the first 
time that qPCR has sufficient sensitivity and specificity 
to use 100 parasite/ml as a treatment threshold without 
affecting trial outcome related to infection and pre-eryth-
rocytic protective efficacy. Therefore, the implementation 
of these diagnostics would improve safety while reducing 
the clinical burden and costs without compromising the 
evaluation of protective efficacy.
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